Effect of bisphosphonates on the rapidly growing male murine skeleton

Endocrinology

Volumn 155, Issue 4, 2014, Pages 1188-1196

  Zhu, Eric D ^a   Louis, Leeann ^a   Brooks, Daniel J ^a   Bouxsein, Mary L ^a   Demay, Marie B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CASPASE 3; CLODRONIC ACID; GELATINASE B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DENSITY; BONE GROWTH; BONE MASS; BONE MATURATION; CARTILAGE CELL; CELL COUNT; CONTINUOUS INFUSION; CONTROLLED STUDY; CORTICAL BONE; DRUG ABSORPTION; ENZYME PHOSPHORYLATION; GROWTH PLATE; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; LABORATORY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL;

ALENDRONATE; ANIMALS; APOPTOSIS; BIOMECHANICAL PHENOMENA; BONE AND BONES; BONE DEVELOPMENT; BONE RESORPTION; CHONDROCYTES; CLODRONIC ACID; DIPHOSPHONATES; HYPERTROPHY; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; PHENOTYPE; X-RAY MICROTOMOGRAPHY;

EID: 84897852685     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1993     Document Type: Article

References (43)

1. Boonen S, Ferrari S, Miller PD, et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective. J Bone Miner Res. 2012;27:963-974.
2. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase iii osteoporosis treatment study group. N Engl J Med. 1995;333:1437-144330.
3. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (vert) study group. JAMA. 1999; 282:1344-1352. (Pubitemid 29483192)
4. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEngl J Med. 2007; 356:1809-1822. (Pubitemid 46698462)
5. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952. (Pubitemid 28455096)
6. Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007:CD005324.
7. Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr. 2002;141:644-651. (Pubitemid 35292762)
8. Falcini F, Bindi G, Simonini G, et al. Bone status evaluation with calcaneal ultrasound in children with chronic rheumatic diseases. A one year followup study. J Rheumatol. 2003;30:179-184. (Pubitemid 36077791)
9. Freundlich M, Alon US. Bisphosphonates in children with hypercalciuria and reduced bone mineral density. Pediatr Nephrol. 2008; 23:2215-2220.
10. Papapoulos SE. Bisphosphonate therapy in children with secondary osteoporosis. Horm Res Paediatr. 2011;76(suppl 1):24-27.
11. Heinrich SD, Gallagher D, Harris M, Nadell JM. Undiagnosed fractures in severely injured children and young adults. Identification with technetium imaging. J Bone Joint Surg Am. 1994;76:561-572. (Pubitemid 24154128)
12. Amanat N, McDonald M, Godfrey C, Bilston L, Little D. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007;22:867-876. (Pubitemid 351339747)
13. Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res. 2004;19:1191-1193. (Pubitemid 41110572)
14. Sabbagh Y, Carpenter TO, Demay M. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci USA. 2005;102:9637-9642. (Pubitemid 40981733)
15. Mansfield K, Teixeira CC, Adams CS, Shapiro IM. Phosphate ions mediate chondrocyte apoptosis through a plasma membrane transporter mechanism. Bone. 2001;28:1-8. (Pubitemid 32112057)
16. Russell RG, Kislig AM, Casey PA, et al. Effect of diphosphonates and calcitonin on the chemistry and quantitative histology of rat bone. Calcif Tissue Res. 1973;11:179-195.
17. Schenk R, Merz WA, Mühlbauer R, Russell RG, Fleisch H. Effect of ethane-1-hydroxy-1,1-diphosphonate (ehdp) and dichloromethylene diphosphonate (cl 2 mdp) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res. 1973;11:196-214.
18. Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta. Bone. 2003;32:268-274. (Pubitemid 36349530)
19. Dimeglio LA, Ford L, McClintock C, Peacock M. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2005;18:43-53. (Pubitemid 40227871)
20. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2006;21:132-140. (Pubitemid 43023235)
21. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types iii and iv osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005;20:977-986. (Pubitemid 40712822)
22. Ward LM, Denker AE, Porras A, et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type i. J Clin Endocrinol Metab. 2005;90:4051-4056. (Pubitemid 41058171)
23. Rauch F, Munns CF, Land C, Cheung M, Glorieux FH. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res. 2009;24: 1282-1289.
24. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types i, iii, and iv. Pediatrics. 2003;111:1030-1036. (Pubitemid 36542617)
25. Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res. 2005;20: 1235-1243. (Pubitemid 40863813)
26. Melchior R, Zabel B, Spranger J, Schumacher R. Effective parenteral clodronate treatment of a child with severe juvenile idiopathic osteoporosis. Eur J Pediatr. 2005;164:22-27. (Pubitemid 40110003)
27. Panigrahi I, Das RR, Sharda S, Marwaha RK, Khandelwal N. Response to zolendronic acid in children with type iii osteogenesis imperfecta. J Bone Miner Metab. 2010;28:451-455.
28. Lefebvre V, Garofalo S, Zhou G, Metsäranta M, Vuorio E, De Crombrugghe B. Characterization of primary cultures of chondrocytes from type II collagen/β-galactosidase transgenic mice. Matrix Biol. 1994;14:329-335. (Pubitemid 24269080)
29. Villikka K, Perttunen K, Rosnell J, Ikävalko H, Vaho H, Pylkkänen L. The absolute bioavailability of clodronate from two different oral doses. Bone. 2002;31:418-421. (Pubitemid 35299623)
30. McCarthy EA, Raggio CL, Hossack MD, et al. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr Res. 2002;52:660-670. (Pubitemid 35286033)
31. Simm PJ, Johannesen J, Briody J, et al. Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis. Bone. 2011;49:939-943.
32. Provot S, Nachtrab G, Paruch J, Chen AP, Silva A, Kronenberg HM. A-raf and b-raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes. Mol Cell Biol. 2008;28:344-357.
33. Miedlich SU, Zalutskaya A, Zhu ED, Demay MB. Phosphate-induced apoptosis of hypertrophic chondrocytes is associated with a decrease in mitochondrial membrane potential and is dependent upon erk1/2 phosphorylation. J Biol Chem. 2010;285:18270-18275.
34. Donohue MM, Demay MB. Rickets in vdr null mice is secondary to decreased apoptosis of hypertrophic chondrocytes. Endocrinology. 2002;143:3691-3694. (Pubitemid 34925746)
35. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25:1468-1486.
36. Mansfield K, Rajpurohit R, Shapiro I. Extracellular phosphate ions cause apoptosis of terminally differentiated epiphyseal chondrocytes. J Cell Physiol. 1999;179:276-286. (Pubitemid 29203152)
37. Giraudo E, Inoue M, Hanahan D. Anamino-bisphosphonate targets mmp-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004;114:623-633. (Pubitemid 39578752)
38. Valleala H, Hanemaaijer R, Mandelin J, et al. Regulation of mmp-9 (gelatinase b) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sci. 2003;73:2413-2420. (Pubitemid 37107352)
39. Kang JH, Choi NK, Kang SJ, et al. Alendronate affects cartilage resorption by regulating vascular endothelial growth factor expression in rats. Anat Rec (Hoboken). 2010;293:786-793.
40. Kim MS, Kim JH, Lee MR, et al. Effects of alendronate on a disintegrin and metalloproteinase with thrombospondin motifs expression in the developing epiphyseal cartilage in rats. Anat Histol Embryol. 2009;38:154-160.
41. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore). 1997;76:266-283.
42. Martinez-Soto T, Pacaud D, Stephure D, Trussell R, Huang C. Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens. J Pediatr Endocrinol Metab. 2011;24:271-274.
43. Misof BM, Roschger P, Baldini T, et al. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone. 2005;36:150-158. (Pubitemid 40128283) Diseases